• 1. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 2. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244

Professional Introduction to Compound with CAS No. 215305-98-9 and Product Name: tert-butyl N-[2-(piperidin-3-yl)ethyl]carbamate

The compound with the CAS number 215305-98-9 and the product name tert-butyl N-[2-(piperidin-3-yl)ethyl]carbamate represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique structural and functional properties, has garnered considerable attention in recent years due to its potential applications in drug development and therapeutic interventions.

At the core of this compound's significance lies its molecular structure, which integrates a tert-butyl group with a N-[2-(piperidin-3-yl)ethyl]carbamate moiety. The tert-butyl group contributes to the compound's stability and lipophilicity, making it an attractive candidate for oral administration and enhancing its bioavailability. Meanwhile, the N-[2-(piperidin-3-yl)ethyl]carbamate segment introduces a piperidine ring, a scaffold commonly found in bioactive molecules known for their ability to interact with biological targets. Piperidine derivatives are widely recognized for their role in modulating enzyme activity and receptor binding, which makes them invaluable in the design of novel therapeutic agents.

Recent research has highlighted the compound's potential in addressing various therapeutic challenges. Studies have demonstrated that derivatives of N-[2-(piperidin-3-yl)ethyl]carbamate exhibit promising pharmacological properties, including anti-inflammatory, analgesic, and neuroprotective effects. These findings have spurred further investigation into the compound's efficacy in treating conditions such as chronic pain syndromes, neurodegenerative diseases, and inflammatory disorders. The structural features of this compound allow it to engage with multiple biological pathways simultaneously, offering a multitargeted approach that could enhance therapeutic outcomes.

The incorporation of the tert-butyl group into the molecular framework also plays a crucial role in optimizing pharmacokinetic profiles. This bulky substituent can prevent rapid metabolism by enzymes such as cytochrome P450 (CYP450), thereby extending the compound's half-life and ensuring sustained therapeutic levels. Additionally, the lipophilic nature of the tert-butyl group facilitates efficient absorption across biological membranes, making it an ideal candidate for formulations requiring systemic delivery.

In vitro studies have revealed that tert-butyl N-[2-(piperidin-3-yl)ethyl]carbamate demonstrates remarkable binding affinity to specific enzymes and receptors implicated in various disease mechanisms. For instance, preliminary data suggest that this compound interacts with monoamine oxidase (MAO) enzymes, which are key players in regulating neurotransmitter levels. By modulating MAO activity, the compound may offer a novel strategy for managing conditions associated with neurotransmitter imbalances.

Moreover, the piperidine moiety within the molecule is known to enhance solubility and improve pharmacokinetic properties, which are critical factors in drug development. This feature allows for greater flexibility in formulation design and administration routes, broadening its potential applications across different therapeutic areas.

Current research is also exploring synthetic pathways to modify this compound further, aiming to enhance its selectivity and reduce potential side effects. By leveraging advanced chemical methodologies such as combinatorial chemistry and high-throughput screening (HTS), scientists are identifying structural analogs that may offer improved efficacy while maintaining safety profiles.

The pharmaceutical industry has taken note of these advancements, with several companies investing in clinical trials to evaluate the therapeutic potential of derivatives based on tert-butyl N-[2-(piperidin-3-yl)ethyl]carbamate. Early-phase trials have shown encouraging results, particularly in patients suffering from chronic pain conditions where traditional treatments have proven inadequate. These findings underscore the importance of innovative compounds like this one in addressing unmet medical needs.

From a regulatory perspective, ensuring compliance with international standards is paramount for advancing compounds like this into clinical practice. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent guidelines for evaluating new drug candidates. Companies developing derivatives of tert-butyl N-[2-(piperidin-3-yl)ethyl]carbamate must navigate these requirements meticulously to bring safe and effective therapies to market.

The integration of computational modeling and artificial intelligence (AI) has further accelerated progress in optimizing this compound's properties. AI-driven platforms enable researchers to predict molecular interactions with high accuracy, facilitating rapid identification of promising candidates for further development. This synergy between traditional chemistry and cutting-edge technology is revolutionizing drug discovery processes.

In conclusion,tert-butyl N-[2-(piperidin-3-yl)ethyl]carbamate, represented by CAS No. 215305-98-9, holds immense promise as a versatile pharmacological entity with broad therapeutic applications. Its unique structural features make it an attractive scaffold for developing novel drugs targeting diverse diseases. As research continues to uncover new insights into its mechanisms of action, this compound is poised to play a pivotal role in shaping future medical treatments.

• 135632-53-0(tert-butyl N-(4-piperidylmethyl)carbamate)
• 165528-81-4(tert-butyl N-[2-(piperidin-4-yl)ethyl]carbamate)
• 879275-33-9(tert-butyl N-[[(3R)-3-piperidyl]methyl]carbamate)
• 885268-87-1(Tert-butyl 3-(piperidin-4-YL)propylcarbamate)
• 1185133-03-2(tert-Butyl (piperidin-4-ylmethyl)carbamate dihydrochloride)
• 1049727-98-1(tert-Butyl (piperidin-4-ylmethyl)carbamate hydrochloride)
• 1158759-03-5(Tert-butyl N-[(4-methylpiperidin-4-yl)methyl]carbamate)
• 142643-29-6(tert-butyl N-(3-piperidylmethyl)carbamate)
• 871727-12-7(Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethylester)
• 871727-19-4(Carbamic acid, [[(3R,4S)-3-methyl-4-piperidinyl]methyl]-,1,1-dimethylethyl ester, rel-)